On June 24, 2019 Oncology Venture A/S (Nasdaq First North Stockholm: OV.ST) reported that the European Patent Office will grant Oncology Venture a patent on the LiPlaCis Drug Response Prediction (DRP) (Press release, Oncology Venture, JUN 24, 2019, View Source [SID1234537233]). The LiPlaCis DRP covers 205 genes and predicts the response in individual patients to the anti-cancer drug LiPlaCis based on a pre-treatment biopsy.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
LiPlaCis is an intelligent, target controlled liposome formulation of one of the world’s most widely used chemotherapies, cisplatin. The specific LiPlaCis formulation allows delivery of LiPlaCis directly at the tumor site. Oncology Venture’s drug specific diagnostic tool DRP selects the patients who are expected to benefit from the treatment. LiPlaCis is showing strong results in an ongoing Phase 2 study in patients with metastatic breast cancer.
The patent from the European Patent Office provides key intellectual property protection in Europe.
"The patent approval is an important value driver in the development of LiPlaCis, since our AI powered DRP technology is instrumental for the strong results we have seen so far in the ongoing Phase 2 study. Together with the well-defined regulatory route towards marketing approval, as announced earlier this month, the new patent provides us with an exceptionally solid platform for the ongoing partnering process", says Peter Buhl Jensen, M.D., CEO of Oncology Venture.
For further information, please contact:
For investor inquiries
Ulla Hald Buhl, IR & Communications
E-mail: [email protected]
Telephone +45 21 70 10 49
For media inquiries
Thomas Pedersen, Carrotize PR & Communications
E-mail: [email protected]
Telephone +45 60 62 93 90
About the Drug Response Predictor – DRP Companion Diagnostic
Oncology Venture uses its multi gene DRP to select those patients who by the genetic signature of their cancer are found to have a high likelihood of responding to the drug. The goal is developing the drug for the right patients, and by screening patients before treatment the response rate can be significantly increased. The DRP method builds on the comparison of sensitive vs. resistant human cancer cell lines, including genomic information from cell lines combined with clinical tumor biology and clinical correlates in a systems biology network. DRP is based on messenger RNA from the patient’s biopsies.
DRP has proven its ability to provide a statistically significant prediction of the clinical outcome from drug treatment in cancer patients in 29 out of 37 clinical studies that were examined and is currently demonstrating promising results in an ongoing phase 2 study prospectively using LiPlaCis and its DRP to track, match and treat patients with metastatic breast cancer.
The DRP platform, i.e. the DRP and the PRP tools, can be used in all cancer types and is patented for more than 70 anti-cancer drugs in the US. The PRP is used by Oncology Venture for Personalized Medicine. The DRP is used by Oncology Venture for drug development.